問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2017-01-20 - 2025-08-15
Condition/Disease
Locally Advanced Head and Neck Squamous Cell Carcinoma
Test Drug
Keytruda
Participate Sites10Sites
Terminated10Sites
Division of Radiation Therapy
Division of Hematology & Oncology
2017-03-01 - 2019-12-31
Triple Negative Breast Neoplasms
Pembrolizumab (MK-3475) ；KEYTRUDA®/吉舒達®
Participate Sites7Sites
Terminated7Sites
Division of General Surgery
2017-08-07 - 2021-12-31
Extensive Stage Small Cell Lung Cancer
Participate Sites8Sites
未分科
Division of Thoracic Medicine
2013-12-01 - 2015-03-31
Participate Sites2Sites
Terminated2Sites
2014-10-01 - 2023-03-16
Non-Small Cell Lung Cancer (NSCLC)
MK-3475
Participate Sites5Sites
Terminated5Sites
2015-03-01 - 2019-06-30
Chronic Hepatitis C
MK-5172A
Study ended1Sites
Digestive System Department
2015-04-01 - 2023-12-31
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pembrolizumab (MK-3475)
Participate Sites6Sites
2015-04-01 - 2020-12-31
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Participate Sites4Sites
Terminated4Sites
2015-04-15 - 2019-12-31
Advanced/Unresectable or Metastatic Urothelial Cancer
Participate Sites3Sites
2017-07-26 - 2020-06-30
Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer
全部
